Ezetimibe
Contents
Description
Ezetimibe is a cholesterol absorption inhibitor that reduces intestinal absorption of dietary and biliary cholesterol. It is used as adjunctive therapy in Schnyder corneal dystrophy to manage systemic hyperlipidemia and potentially reduce corneal lipid deposition. It is often combined with statins for enhanced lipid-lowering effects.
Indications & Therapeutic Use
primary hypercholesterolemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia, Schnyder corneal dystrophy
Linked Diseases:
Global Availability (11 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Ezetimibe — GNH India
374 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | ezetimibe |
| Brands | 1 brand available |
| Active Ingredient | ezetimibe |
| Drug Class | primary hypercholesterolemia |
| Manufacturer | Merck |
| Dosage Forms | oral tablet 10mg |
| Medical Code | C10AX09 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 11 countries |